Helicobacter Pylori Eradication Rate Clinical Trial
Official title:
Efficacy of Short-message-based Re-education (SMRE) on Helicobacter Pylori Eradication
Helicobacter pylori (H. pylori) is a pathogen that infects more than 50% of the human population, resulting in high healthcare costs worldwide. However, H. pylori eradication rate is low nowadays and patients's compliance is one of the most important effective factors.
| Status | Recruiting |
| Enrollment | 310 |
| Est. completion date | January 2017 |
| Est. primary completion date | January 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - outpatients aged 18-70 years - confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture - an intention of H. pylori eradication treatment and have written inform consent - ability to read short messages on the mobile phone Exclusion Criteria: - advanced chronic disease that would not allow the patient to complete the treatment or follow-up or attend visits - allergy to any of the drugs used in this study - previous Helicobacter Pylori eradication treatment - pregnancy or breastfeeding (female participants with childbearing potential were required to use medically accepted contraception for the duration of the study) - taking antibiotics or PPIs or bismuth salts within four weeks - previous gastrointestinal surgery |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | Department of Gastroenterology, Qilu Hospital, Shandong University | Jinan | Shandong |
| Lead Sponsor | Collaborator |
|---|---|
| Shandong University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | The different rate of adverse events between 2 groups | 8 months | No | |
| Other | The different rate of symptom remissions after Hp eradication therapy between 2 groups | 8 months | No | |
| Primary | The difference of H. pylori eradication rate between two groups | 8 months | No | |
| Secondary | Rate of non-compliance with instructions between 2 groups | 8 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02776371 -
Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori
|
Phase 4 | |
| Not yet recruiting |
NCT05196945 -
Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study
|
Phase 4 | |
| Completed |
NCT05719831 -
Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection
|
Phase 3 |